Development Pharmaceutics of Microbicide Formulations. Part II: Formulation, Evaluation, and Challenges
- 1 August 2003
- journal article
- review article
- Published by Mary Ann Liebert Inc in AIDS Patient Care and STDs
- Vol. 17 (8) , 377-399
- https://doi.org/10.1089/108729103322277402
Abstract
In recent years, AIDS and sexually transmitted diseases (STDs) have become a burgeoning problem and are spreading at an alarming rate. Microbicides are being developed as a new therapeutic category for prevention of transmission of sexually transmitted infections (STIs) and HIV. Many of the microbicide formulations (MF) may fail to elicit a protective response either because of a lack of efficacy or inadequate formulation. Manufacturing a stable, efficacious, safe, and optimal product is the main objective of formulation development programs. Preformulation parameters (PP), as discussed in Part I of this series, influence formulation development significantly and should be considered carefully before designing a formulation strategy. Initially, based on PP and market research, a target product profile (TPP) is generated, which defines product attributes that can be normally classified as "essential" and "desirable." A complex and dynamic process begins thereafter that takes into consideration myriad factors starting from selection of delivery system, selection of excipients, compatibility study, prototype composition, selection of process and optimization, stability testing, scale up, manufacturing under good manufacturing practices (GMP), and packaging development. Prototype formulations are evaluated for several performance characteristics (e.g., dispersion behavior, bioadhesion, retention, spreading, rheology). These compositions are also subjected to biologic evaluation by various in vitro and in vivo models. Such a well-planned, well-coordinated, and well-implemented formulation development program not only accelerates overall development but also minimizes failures in subsequent clinical development studies. The objective of this review is to highlight the importance of formulation science, outline the steps involved in this process, and explore how these can be exploited for achieving optimal MF.Keywords
This publication has 70 references indexed in Scilit:
- Sustained release bioadhesive effervescent ketoconazole microcapsules tabletted for vaginal deliveryJournal of Microencapsulation, 2002
- Assemblies for In Vitro Measurement of Bioadhesive Strength and Retention Characteristics in Simulated Vaginal EnvironmentDrug Development and Industrial Pharmacy, 2002
- Microbicide for Prevention of Sexually Transmitted Diseases Using a Pharmaceutical ExcipientAIDS Patient Care and STDs, 2000
- Effect of undecylenic acid as a topical microbicide against genital herpes infection in mice and guinea pigsAntiviral Research, 1999
- Reducing the Risk of Chlamydia trachomatis Genital Tract Infection by Evaluating the Prophylactic Potential of Vaginally Applied ChemicalsClinical Infectious Diseases, 1995
- Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutesJAMA, 1992
- Preferences of Women for Use of Intravaginal MedicationsDrug Development and Industrial Pharmacy, 1991
- A disintegration test for vaginal tablets: comparison with BP testJournal of Pharmacy and Pharmacology, 1990
- Physico-chemical properties of water insoluble polymers important to mucin/epithelial adhesionJournal of Controlled Release, 1985
- An in-vitro investigation of mucosa-adhesive materials for use in controlled drug deliveryJournal of Pharmacy and Pharmacology, 1984